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ABSTRACT
Focal and segmental glomerulosclerosis (FSGS) is one of the most
important renal diseases related to end-stage renal failure. Bradykinin
has been implicated in the pathogenesis of renal inflammation,
whereas the role of its receptor 2 (B2RBK; also known as BDKRB2)
in FSGS has not been studied. FSGS was induced in wild-type and
B2RBK-knockout mice by a single intravenous injection of Adriamycin
(ADM). In order to further modulate the kinin receptors, the animals
were also treated with the B2RBK antagonist HOE-140 and the
B1RBK antagonist DALBK. Here, we show that the blockage of
B2RBK with HOE-140 protects mice from the development of FSGS,
including podocyte foot process effacement and the re-establishment
of slit-diaphragm-related proteins. However, B2RBK-knockout mice
were not protected from FSGS. These opposite results were due to
B1RBK expression. B1RBK was upregulated after the injection of
ADM and this upregulation was exacerbated in B2RBK-knockout
animals. Furthermore, treatment with HOE-140 downregulated the
B1RBK receptor. The blockage of B1RBK in B2RBK-knockout
animals promoted FSGS regression, with a less-inflammatory
phenotype. These results indicate a deleterious role of both kinin
receptors in an FSGS model and suggest a possible cross-talk
between them in the progression of disease.
KEY WORDS: Focal and segmental glomerulosclerosis, Bradykinin
receptors, Inflammation, Podocyte, Fibrosis
INTRODUCTION
Kinins are powerful pro-inflammatory peptides (Bhoola et al., 1992;
Campos and Calixto, 1995; Kang et al., 2004). Kinins are generated
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by the action of kallikrein enzymes on kininogen substrates. Two
types of kallikrein enzymes are known, tissue and plasmatic
kallikreins, which act on low-molecular-mass kininogens and high-
molecular-mass kininogens, respectively (Regoli and Barabé, 1980;
Campbell, 2001). The actions of these enzymes on their substrates
generate bradykinin and kallidin, active peptides that signal through
a constitutive G-protein-coupled receptor called the B2 receptor
(B2RBK; also known as BDKRB2) (Bhoola et al., 1992; Marin
Castaño et al., 1998). B2RBK is responsible for many of the
physiological actions of kinins – such as decreasing blood pressure
(Campos and Calixto, 1995), regulating blood flow, relaxing smooth
muscle, enabling vascular permeability and nitric oxide release
(Roman-Campos et al., 2010) and reducing oxidative stress (Xia et
al., 2006). Despite its physiological role, B2RBK can also induce
the activation of pro-inflammatory (Campos and Calixto, 1995;
Marceau and Bachvarov, 1998; Calixto et al., 2000) and pro-fibrotic
(Douillet et al., 2000; Stadnicki et al., 2005) cascades, which can, in
turn, induce tissue damage.
Although B2RBK plays an important role in renal physiology per
se, in some circumstances, the upregulation of B2RBK can lead to
heterodimerization with the inducible B1 bradykinin receptor
(B1RBK; also known as BDKRB1) (Barki-Harrington et al., 2003;
Kang et al., 2004) and/or angiotensin type-1 receptor (AbdAlla et al.,
2000; AbdAlla et al., 2001), contributing to the activation of these
already known renal disease-related receptors (Wang et al., 2008;
Wang et al., 2009; Pereira et al., 2011; Tunçdemir et al., 2011).
In the literature, we found different results concerning the role of
B2RBK on fibrosis-related diseases, especially in renal tissue.
Several papers describe a protective role for B2RBK (Wang et al.,
2000a; Schanstra et al., 2002; Kakoki et al., 2010), whereas others
describe a deleterious one (Dos Santos et al., 2008; Naito et al.,
2010). Additionally, some groups report a dual role for B2RBK
(Marin Castaño et al., 1998), which acts in physiological and
inflammatory responses that are associated with cAMP and the
release of phospholipase C, suggesting that there are different
binding sites for the B2RBK ligand bradykinin, which could
subsequently affect the signal transduction of this receptor. Our
group has recently demonstrated the deleterious role of B1RBK in
a focal and segmental glomerular sclerosis (FSGS) experimental
model (Pereira et al., 2011). We also observed an upregulation of
B2RBK. FSGS is one of the most important renal diseases that is
related to end-stage renal failure; furthermore, an individual that is
diagnosed with FSGS has a poor prognosis, which worsens when
they present with high proteinuria. Most cases lead to end-stage
renal disease within 5 years after the first signs of the illness
(LeBrun et al., 2000; Seikaly et al., 2001; Franceschini et al., 2003;
Deegens et al., 2008). 
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The role of B2RBK in the progression of FSGS is unknown, and
few studies have reported it as a potential therapeutic target. Here,
we unveil a role for this kinin receptor by demonstrating that
B2RBK and B1RBK cross-talk in order to promote inflammation,
resulting in an alteration of the permselectivity of glomerular
membrane.
RESULTS
Early blockage of B2RBK protects animals from the first
signs of FSGS
As detailed in recent papers (Pereira et al., 2011; Pereira et al., 2012;
Reis et al., 2012), we have shown that the experimental model 
of FSGS is characterized by proteinuria, albuminuria,
glomerulosclerosis and inflammation. Therefore, to evaluate the role
of B2RBK in FSGS, we blocked this receptor by using the
antagonist HOE-140 and then examined the effect on the
aforementioned parameters. In the first protocol, we treated animals
with HOE-140 at days 1, 2 and 3 after the injection of Adriamycin
(ADM; also known as doxorubicin) and euthanized the animals at
day 4, a timepoint at which proteinuria could be detected.
The early blockage of B2RBK protected animals from the
proteinuria and albuminuria that was induced by the injection of
ADM (Fig. 1A,B). The treatment was also effective at preventing
the downregulation of the expression of the mRNAs encoding WT-
1 (Fig. 1C) and podocin (also known as NPHS-2) (Fig. 1D);
however, the treatment did not alter the expression of nephrin (also
known as NPHS-1) or α-actinin-4 mRNAs (Fig. 1E,F).
The levels of pro-inflammatory cytokines have been linked to
FSGS progression. In particular, the cytokine IL-1β has been
shown to be one of the main molecules that is related to B1RBK
expression (Klein et al., 2009; Pereira et al., 2011; Pereira et al.,
2012; Reis et al., 2012). Therefore, we also quantified the
expression of B1RBK mRNA. We observed that the treatment
with HOE-140 was effective in downregulating the expression of
IL-1β (Fig. 1G) and B1RBK (Fig. 1H) mRNAs, despite the fact
that the renal levels of the IL-1β protein (supplementary material
Fig. S1A) did not achieve statistical significance between the
groups. The levels of other cytokines, such as tumor necrosis
factor (TNF)-α and IL-17, showed no difference between the
groups (supplementary material Fig. S1B-D).
Another important parameter to evaluate in FSGS is the renal
expression of pro-fibrotic proteins. We observed that TGFβ-1
(hereafter referred to as TGF-β), plasminogen activator inhibitor
type 1 (PAI-1; also known as SERPINE1) and connective tissue
growth factor (CTGF) mRNA levels were downregulated after
treatment with HOE-140 (Fig. 1I-K). The renal histology analysis at
day 4 did not show any significant difference in the segmental
sclerosis index, but the animals that had been treated with HOE-140
presented less mesangial hypercellularity, an important marker of
FSGS progression (supplementary material Fig. S2A-D). Owing to
the importance of macrophage infiltration in FSGS (Diamond and
Pesek-Diamond, 1991; Ohtaka et al., 2002), we evaluated the renal
protein levels of macrophage chemokines, but at this timepoint, the
groups presented no significant difference between them
(supplementary material Fig. S2E-H).
Delayed blockage of B2RBK with HOE-140 reverses FSGS
In this protocol, we treated animals with HOE-140 at days 4, 5 and
6 after ADM injection. At this timepoint, signs of FSGS – such as
albuminuria, downregulation of podocyte-related proteins and
upregulation of inflammatory related cytokines (Pereira et al.,
2011) – were already established. The animals were then
euthanized at day 7. Treatment with HOE-140 diminished the
ADM-induced proteinuria and albuminuria (Fig. 2A,B) that is
associated with FSGS. We observed the protection of podocyte
structure and the preservation of nephrin and WT-1 mRNA
expression (Fig. 2C,F), but no differences were found in the
expression of mRNAs encoding podocin and α-actinin-4 (Fig.
2D,E). Furthermore, animals that had been treated with HOE-140
showed less podocyte damage, as observed by using electron
microscopy (Fig. 2G).
Using HOE-140, we observed that blockage of B2RBK efficiently
reversed the upregulation of the expression of pro-inflammatory
cytokine proteins (Fig. 3A-C), including TNF-α, IL-1β and IL-17.
The upregulation of IL-1 β mRNA expression was also abrogated
upon B2RBK blockage (Fig. 4A). Interestingly, B2RBK blockage
inhibited the expression of B1RBK mRNA (Fig. 4B).
Because macrophage infiltration is a common finding in FSGS
experimental models (Diamond and Pesek-Diamond, 1991; Ohtaka
et al., 2002; Pereira et al., 2011), we evaluated the role of B2RBK
blockage on the renal expression of macrophage-related proteins
(Fig. 3D-F) and also on the expression of monocyte chemoattractant
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TRANSLATIONAL IMPACT
Clinical issue 
Focal and segmental glomerulosclerosis (FSGS) is one of the major
causes of end-stage renal diseases worldwide. FSGS is characterized
by sclerotic lesions in glomeruli, and, at the clinical level, a classic
hallmark is proteinuria (the presence of proteins in urine). Proteinuria is
caused by an increase in permeability to proteins, which is induced by
alterations in the structure and function of specialized glomerular cells
called podocytes. Mutations in podocyte-related proteins, including
nephrin and podocin, can give rise to FSGS; however, in most cases, the
origin of disease is unknown. Experimental models of FSGS have been
used since the 1980s and have helped to clarify many molecular aspects
of the disease progression, such as the role of inflammation and the
involvement of renin-angiotensin and kinin-kallikrein systems. Recent
work showed the importance of kinin receptor 1 (B1RBK) in an
experimental model of FSGS, providing incentive for further research into
the role of kinin receptors in this disease.
Results
In this work, knockout animals and kinin receptor antagonists were used
to unveil the role of kinin receptor 2 (B2RBK) in FSGS. The disease was
induced in wild-type and B2RBK-knockout mice, using a previously
established approach. In wild-type mice, blockage of the receptor with
antagonists prevented FSGS when administered soon after disease
induction and reversed signs of disease – including proteinurea – when
administered during the later stages. Treatment with the B2RBK
antagonist also downregulated fibrotic and inflammatory proteins that are
associated with renal lesions. The authors report that FSGS is
exacerbated in B2RBK-knockout mice, and, consistent with previous
studies, higher B1RBK receptor expression was observed in these
animals. Interestingly, treatment of B2RBK-knockout mice with a B1RBK
antagonist ameliorated disease.
Implications and future directions
FSGS is associated with high morbidity and mortality worldwide,
emphasizing the importance of searching for molecular targets that could
reverse the clinical and histological features of, and even stabilize,
disease progression. The results reported here indicate that kinin
receptors are potentially important targets in FSGS, because their
blockage with antagonists can restore podocyte architecture and protect
against clinical symptoms, such as proteinuria. Although this work
focused primarily on B2BRK, the data suggests cross-talk between the
two receptors, which should be explored further in future studies. The
understanding of molecular mechanisms provided by experimental

















protein 1 (MCP-1, also known as CCL2) mRNA (supplementary
material Fig. S3A).
Fibrotic markers, such as PAI-1 and TGF-β, were also
downregulated in mice that had been treated with HOE-140
(Fig. 4C,D).
Finally, the group that had been treated with HOE-140 showed
less tubular damage and renal sclerosis, as observed by renal
histology (supplementary material Fig. S3B-E).
HOE-140 induces sustained protection during FSGS
progression
After evaluating the efficacy of treatment with HOE-140 in the first
two short-term protocols, we evaluated the same protocols over a
longer term – after 21 days of ADM injection, a phase that is
characterized by extensive sclerosis and renal damage.
Both protocols were efficient in preventing proteinuria (data not
shown) and albuminuria (Fig. 5A). The expression of fibrotic
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Fig. 1. Early HOE-140 treatment
protects mice from the development
of FSGS. Four days after the injection
of 10 mg of Adriamycin (ADM) per kg
of bodyweight, Balb/c mice were killed.
HOE-140 treatment protected mice
from proteinuria (A) and albuminuria
(B). HOE-140 also prevented the
downregulation of the mRNAs
encoding the podocyte proteins WT-1
(C) and podocin (NPHS-2) (D);
however, HOE-140 did not affect the
levels of nephrin (NPHS-1) (E) and α-
actinin-4 (ACTN-4) (F) mRNA that were
induced by ADM injection. The
treatment also prevented the
upregulation of mRNAs for the pro-
inflammatory (IL-1β and B1RBK) (G,H)
and pro-fibrotic markers TGF-β (I), PAI-
1 (J) and CTGF (K). Expression of the
mRNAs were normalized to that of
hypoxanthine guanine phosphoribosyl
transferase (HPRT). *P<0.05 compared
with that of control mice, #P<0.05
compared with that of mice treated with


















markers, such as TGF-β mRNA, was also downregulated in HOE-
140-treated animals (Fig. 5B). We observed that HOE-140
prevented the downregulation of podocyte proteins (Fig. 5C,D) and
foot process effacement (Fig. 5E).
Overexpression of B1RBK in B2RBK-knockout animals is
associated with FSGS exacerbation
We further used genetically modified animals to study the role of
B2RBK in FSGS. As many reports have shown (Wang et al., 2000b;
Fogo, 2003; Pereira et al., 2011; Pereira et al., 2012; Reis et al.,
2012), the experimental models of FSGS are predominantly
generated in the Balb/c mouse strain. However, recent papers have
demonstrated the possibility of adapting this method to establish the
disease in Black/6 mice, thus raising new possibilities (Jeansson et
al., 2009).
As Fig. 6A,B shows, B2RBK-knockout animals were more
prone to developing ADM-induced FSGS because the animals
showed increased proteinuria and albuminuria compared with that
in wild-type mice in the same background. These results were
supported by the downregulation of podocyte-related proteins and
more podocyte foot process effacement and fusion in the knockout
mice (Fig. 6C-E).
Previous data has shown that the B2RBK-knockout animals
present with increased expression of B1RBK, which has devastating
effects when activated in FSGS (Pereira et al., 2011). Initially, 
we confirmed that these animals highly expressed B1RBK
(supplementary material Fig. S4A) and lacked B2RBK expression
(supplementary material Fig. S4B). Finally, to examine the possible
cross-talk between these two receptors, we blocked B1RBK with its
specific antagonist DALBK in B2RBK-knockout animals.
Surprisingly, we observed signs of protection from FSGS, including
a reduction in podocyte foot process effacement and pro-fibrotic
TGF-β expression (Fig. 6 and supplementary material Fig. S4).
DISCUSSION
Recently, the deleterious role of B1RBK in FSGS has been
described, where the activation of this receptor was associated with
the upregulation of fibrotic and pro-inflammatory cytokines, such as
TGF-β and IL-1β. IL-1β is one of the principal inducers of this
receptor. Additionally, downregulation of podocyte proteins and
podocyte foot process effacement was observed (Niemir et al., 1997;
Kim et al., 2003; Schramek et al., 2009; Lee and Song, 2010; Lee,
2012). In this work, we focused our attention on the role of B2RBK,
the other receptor that is associated with kinin signaling. In the
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Fig. 2. Delayed HOE-140
treatment protects mice from the
development of FSGS. At day 7
after treatment with 10 mg of
Adriamycin (ADM) per kg of
bodyweight, balb/c mice were killed.
Treatment with HOE-140 protected
mice from proteinuria (A) and
albuminuria (B). HOE-140 also
prevented the downregulation of the
mRNAs that encode the podocyte
proteins nephrin (NPHS-1) (C), and
WT-1 (F), although the treatment
showed no difference in podocin
(NPHS-2) (D) and α-actinin-4
(ACTN-4) (E) between groups.
Expression of the mRNAs were
normalized to that of hypoxanthine
guanine phosphoribosyl transferase
(HPRT). (G) We observed, by using
electron microscopy analysis, that
HOE-140 prevented the podocyte
foot process effacement that was
induced by ADM injection. The
black arrow indicates podocyte
effacement. *P<0.05 compared with
that of control mice, #P<0.05
compared with that of mice treated
with only ADM. Five animals were
















literature, different results concerning renal kinin receptor blockage,
or the lack of this receptor, have caused debate (Marin Castaño et
al., 1998; Wang et al., 2000a; Schanstra et al., 2002; Dos Santos et
al., 2008; Kakoki et al., 2010). In the first part of this work, we
blocked B2RBK with the specific antagonist HOE-140 in the classic
model of FSGS. Our treatments were performed according to the
level of kinin receptor expression during FSGS (Pereira et al., 2011;
Pereira et al., 2012). First, we blocked B2RBK at the beginning of
disease progression. We observed, as some papers have shown
(Braun et al., 2002; Dos Santos et al., 2008; Naito et al., 2010), that
similar to B1RBK, B2RBK blockage can control proteinuria and
albuminuria levels in animals. Furthermore, this positive result was
reinforced by the maintenance of podocyte-related protein
expression, which is, normally, downregulated in FSGS human and
experimental models (Saleem et al., 2002; Pereira et al., 2011;
Zheng et al., 2012). Associated with this protection, we observed the
reduced expression of fibrosis-related proteins – such as TGF-β,
PAI-1, vimentin and CTGF – which are usually upregulated in renal
disorders (Chang et al., 2009; Klein et al., 2009; Ng et al., 2009).
Another important finding of this treatment protocol was the
downregulation of an important cytokine that is found in FSGS –
IL-1β, which is linked to B1RBK upregulation (Ahluwalia and
Perretti, 1996; Phagoo et al., 2001). These results demonstrate that
HOE-140 could indirectly favor B1RBK downregulation, which can
contribute to a better outcome of FSGS. Previous data have already
indicated that B1RBK downregulation is associated with lower
expression levels of TNF-α and IL-1β after treatment with HOE-140
(Abraham et al., 1991; Bandeira-Melo et al., 1999; Souza et al.,
2003; Sainz et al., 2004; Souza et al., 2004). This possible cross-talk
between the two receptors requires further investigation.
The second delayed-treatment protocol led to a better disease
outcome, primarily because the animals had less proteinuria and
albuminuria, and increased preservation of podocyte structure (as
observed by electron microscopy), markers that are associated with
better prognosis in FSGS (Wagner et al., 2008). Furthermore, the
animals had less macrophage infiltration and renal and tubular
lesions, other important biomarkers of FSGS progression (Klein et
al., 2009; Pereira et al., 2011).
Finally, to evaluate the effects of long-term treatment with HOE-
140, we treated the animals as in the first two protocols but then
killed them at day 21, a timepoint at which the disease has
significantly progressed, as observed in other papers that have been
published by our group (Pereira et al., 2011; Pereira et al., 2012;
Reis et al., 2012). Although all treatments reduced FSGS
progression, the long-term treatment with HOE-140 in the final
experiments led to reduced levels of sclerosis and albuminuria; we
have observed previously that peaks in the levels of sclerosis and
albuminuria correlated with the peaks of B2RBK expression in
FSGS (Pereira et al., 2011). Therefore, higher levels of this receptor
are associated with disease progression, suggesting cooperative
signaling of kinin receptors in the development of FSGS. In
particular, B2RBK blockage was associated with B1RBK
downregulation, as observed previously (Seguin et al., 2008; Klein
et al., 2009).
To understand the conflicting results in the literature when
B2RBK-knockout animals are used, we evaluated markers of FSGS
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Fig. 3. Delayed treatment with HOE-140 protects mice from renal expression of pro-inflammatory and macrophage-related proteins that are induced
by Adriamycin injection. Parameters were analyzed at 7 days after the injection of Adriamycin (ADM). HOE-140 prevented the upregulation of the expression
of TNF-α renal protein (A) and renal protein expression of IL-1β (B) and IL-17 (C). The blockage of B2RBK also efficiently prevented the upregulation of the
renal expression of macrophage-related chemokines, such as MCP-1 (D), macrophage inflammatory protein 1 α (MIP-1; also known as CCL3) (E) and
RANTES (regulated on activation, normal T cell expressed and secreted; also known as CCL5) (F). *P<0.05 compared with that of control mice, #P<0.05

















in these animals. Because B2RBK-knockout animals have been
previously generated in the C57 black/6 background, we adapted our
model into these animals, as performed previously by Jeansson and
colleagues (Jeansson et al., 2009).
To our surprise, B2RBK knockout had different results compared
with blockage of B2RBK. These animals showed increased
albuminuria, increased podocyte foot process effacement,
downregulation of podocyte-related proteins, upregulation of fibrotic
molecules and increased glomerulosclerosis. Taken together, these
results indicated that blockage of B2RBK is associated with
protection from FSGS and that B2RBK-knockout animals are more
prone to developing the disease.
The key difference between the two analyses seems to be the
expression of B1RBK in these treatments. B1RBK has been
extensively associated with kidney disease progression (Christopher
and Jaffa, 2002; Klein et al., 2009; Wang et al., 2009), and
inflammatory and fibrotic states (Ahluwalia and Perretti, 1996;
Ricupero et al., 2000; Ni et al., 2003; Westermann et al., 2008;
Westermann et al., 2009). Furthermore, polymorphisms in both
receptors have been associated with renal diseases (Bachvarov et al.,
1998; Maltais et al., 2002; Zychma et al., 2003). B2RBK blockage
with HOE-140 seems to be associated with B1RBK downregulation;
however, we observed B1RBK upregulation in B2RBK-knockout
animals, suggesting that B1RBK expression compensates for the
loss of B2RBK, as has been observed previously by other groups
(Xia et al., 2006; Klein et al., 2009; Kakoki et al., 2010). To test our
hypothesis, we blocked B1RBK in B2RBK-knockout animals. To
our surprise, the blockage of B1RBK attenuated FSGS progression,
and the animals showed less podocyte foot process effacement.
Although there is little data in the literature concerning the role of
kinin receptors in FSGS, our work provides important information
that contributes to a better understanding of the complex role of
kinin receptors in FSGS, an exciting area in which we hope to
instigate further studies. This work primarily focused on the role of
B2RBK; however, we conclude that when the mRNAs for both
receptors are upregulated, both of the kinin receptors can contribute
to disease progression. Cross-talk between the receptors might be
mediated by the upregulation of pro-inflammatory and pro-fibrotic
molecules, which are closely related to FSGS progression. Finally,
care should be taken when kinin-receptor-knockout animals are used
because receptor compensation can affect disease progression.
MATERIALS AND METHODS
Animals
Isogenic male BALB/c, C57 black/6 and C57 black/6 B2RBK-knockout
mice, aged 8-12 weeks (23-28 g), were obtained from the Animal Care
Facility at the Federal University of São Paulo (UNIFESP). All animals
were housed in individual standard cages and had free access to water and
food. All procedures had been previously reviewed and approved by the
internal ethical committee of the institution, adhering to the National
Institutes of Health Guide for the Care and Use of Laboratory Animals, or
equivalent.
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Fig. 4. Delayed HOE-140 treatment protects mice from renal expression of mRNAs that encode pro-inflammatory and pro-fibrotic molecules that are
induced by Adriamycin injection. The parameters were analyzed at 7 days after the injection of 10 mg of Adriamycin (ADM) per kg of bodyweight into balb/c
mice. HOE-140 prevented the upregulated expression of IL-1β mRNA (A). The blockage of B2RBK was also efficient in preventing the upregulation of B1RBK
mRNA expression (B) and the pro-fibrotic molecules PAI-1 (C) and TGF-β (D). Expression of the mRNAs were normalized to that of hypoxanthine guanine
phosphoribosyl transferase (HPRT). *P<0.05 compared with that of control mice, #P<0.05 compared with that of mice treated with only ADM. Five animals were

















FSGS was induced by a single tail-vein injection of Adriamycin (ADM;
doxorubicin hydrochloride; Pfizer, New York, NY) (Wang et al., 2000b; Zheng
et al., 2006). In the balb/c mouse background, a 10 mg/kg dose of ADM was
injected to induce the disease (Pereira et al., 2011; Pereira et al., 2012). In the
C57black/6 strain, a higher dose of 25 mg/kg ADM was used (Jeansson et al.,
2009). An equal volume of saline was given to the control groups.
Modulation of B2RBK in FSGS
B2RBK was modulated using different protocols. First, for the balb/c mice,
the animals were treated with an intravenous injection of the B2RBK
antagonist HOE-140 (Sigma, St Louis, MO) (30 μg per animal) (Zuccollo
et al., 1996a; Zuccollo et al., 1996b) on days 1-3 after ADM injection. The
animals were killed on days 4 and 21. In the second protocol (delayed
treatment), the animals received HOE-140 on days 4-6 and were killed on
days 7 and 21.
Modulation of B1RBK
For the C57 black/6 strain, FSGS was induced by a single dose of ADM in
wild-type and B2RBK-knockout mice. On days 1 and 6 after ADM
injection, the animals were treated intraperitoneally with 10 mg/kg (Pereira
et al., 2011) of the specific B1RBK receptor antagonist des-arg9-leu8-BK
(DALBK) (Sigma, St Louis, MO).
Renal function analyses
On days 1, 4, 7 and 21 after ADM injection, urinary and blood samples were
collected. The urinary protein:creatinine ratio and albuminuria were used to
estimate renal and podocyte function. At the time of killing, blood and urine
were collected. All samples were analyzed using Labtest Diagnosis (Belo
Horizonte, State of Minas Gerais, Brazil) and Sensiprot for protein
measurements. To estimate the urinary albumin concentration, 10 μl of urine
(adjusted to 1 mg/ml), corrected for urinary creatinine level, was separated
by 10% SDS-PAGE and stained with Coomassie Blue.
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Fig. 5. Treatment with HOE-140
induced sustained protection of
mice from FSGS development. The
balb/c mice were divided into two
groups. In the first group, the mice
were treated with HOE-140 at days 1, 2
and 3 after the injection of Adriamycin
(ADM) (early treatment), and in the
second group, the mice were treated
with HOE-140 at days 4, 5 and 6 after
the injection of ADM (delayed
treatment). At the end of the two
protocols, the mice were killed at day
21. Treatment with HOE-140, in both
groups, protected mice from
albuminuria (A). HOE-140 also
prevented the upregulation of TGF-β
mRNA (B) and prevented the
downregulation of nephrin (NPHS-1)
(C). Expression of the mRNAs were
normalized to that of hypoxanthine
guanine phosphoribosyl transferase
(HPRT). HOE-140 also prevented the
downregulation of the WT-1 staining
that was induced by ADM injection, as
observed by immunohistochemistry
(D). ADM 21D, day 21 after injection of
ADM; HOE treatment 1, early
treatment; HOE treatment 2, delayed
treatment. Black arrows indicate WT-1-
positive cells. Scale bars: 50 µm.
(E) By using electron microscopy
analysis, we observed that HOE-140
prevented the podocyte foot process
effacement that was induced by
Adriamycin injection. Black arrow
indicates podocyte effacement.
*P<0.05 compared with that of control
mice, #P<0.05 compared with that of
mice treated with only ADM. Five

















The density of the bands was analyzed using the GeneSnap and Gene
Tools software (Syngene, Cambridge, UK).
Serum cytokine measurement
A Bio-Plex mouse cytokine assay kit (Bio-Rad) was used to test samples for
the presence of kidney tissue cytokines. The assay was read on a Bio-Plex
suspension array system, and the data were analyzed using Bio-Plex Manager
software version 4.0. Standard curves ranged from 32,000 to 1.95 pg/ml.
Determination of active TGF-β protein levels
Active TGF-β protein was measured using a TGF-β Emax immunoassay
system (Promega), according to the manufacturer’s instructions. The results
are presented as TGF-β pg/mg of total protein, measured using the Bradford
assay (Bio-Rad, Hercules, CA).
Gene expression
Kidney samples were frozen in liquid nitrogen. Total RNA was isolated
using TRIzol Reagent (Invitrogen, Carlsbad, CA).
First-strand cDNAs were synthesized using Moloney murine leukemia
virus reverse transcriptase (Promega, Madison, WI).
Real-time PCR was performed using TaqMan primers and probes for
NPHS-1 (TaqMan probe Mm004497831_g1), vimentin (TaqMan probe Mm
00801666-g1), TNF-α (TaqMan probe Mm0136932), PAI-1 (TaqMan probe
Mm 009312), CTGF (TaqMan probe Mm01192932), WT-1 (TaqMan probe
Mm 01337053_m1), IL-1β (TaqMan probe Mm00434228), TGF-β (TaqMan
probe Mm01178820) and COL-1 (TaqMan probe Mm00801666) (Applied
Biosystems, Foster City, CA). For the analyses of B1RBK, B2RBK, NPHS-
2, α-ACTININ-4 and MCP-1, real-time PCR was performed using a SYBR
green assay (Applied Biosystems; Table 1).
The cycling conditions for both TaqMan and SYBR green primers were as
follows: 10 minutes at 95°C, followed by 45 cycles of 30 seconds at 95°C, 30
seconds at 60°C and 30 seconds at 72°C. The relative quantification of mRNA
levels was performed as described in detail in User Bulletin 2 (PerkinElmer,
Applied Biosystems, Branchburg, NJ, 1997). Briefly, the target gene amount
was normalized to the endogenous reference [hypoxanthine
phosphoribosyltransferase 1 (HPRT); SYBR green] and then related to a
calibrator (sample with the lowest expression, namely the controls) using the
formula 2−DDCt. Hence, all data that are expressed as an n-fold difference are
related to the expression of matched controls. Analyses were performed with
the Sequence Detection Software 1.9 (Applied Biosystems, Foster City, CA).
Western blotting
Briefly, 50 μg of total protein from renal tissue was collected and then diluted
in sample buffer (Bio-Rad) containing 20 mg/ml of 2-β-mercaptoethanol
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Fig. 6. The lack of B2RBK receptor exacerbates Adriamycin nephropathy. C57-black-background mice were killed at day 7 after Adriamycin (ADM)
injection. The lack of B2RBK (B2KO) exacerbates the ADM-induced proteinuria (A) and albuminuria (B), and these effects were downregulated by treatment
with DALBK. ADM injection downregulated nephrin (NPHS-1) protein expression in B2RBK-knockout mice, and this downregulation was prevented by DALBK
(C), as shown by western blotting (upper panel). The lower panel shows the quantification of the western blot analyses, where the level of nephrin was
normalized to that of β-actin for each sample. (D) We observed that DALBK protects B2RBK-knockout mice from podocyte foot process effacement, by using
electron microscopy. The black arrow indicates podocyte effacement. *P<0.05 compared with that of control mice, **P<0.05 vs all other groups, #P<0.05
















(Sigma, St Louis, MO). The antibodies used were against β-actin (1:1000;
Sigma, St Louis, MO) and NPHS-1 (1 ug/mL; Abcam, Cambridge, UK).
Western blotting was performed according to the Abcam manufacturer’s
protocols found at www.abcam.com/ps/pdf/protocols/WB-beginner.pdf.
Renal histology analysis
Kidney samples were fixed in 10% neutral formalin. Paraffin sections (3 mm
in thickness) were cut and stained with hematoxylin and eosin. The sections
were analyzed by using a trinocular optical microscope (Olympus
Corporation, Tokyo, Japan). Photographs were taken by using a digital
camera that was coupled to the microscope, and the images were captured
by using with the Pinnacle Studio Plus software (Pinnacle Systems,
Buckinghamshire, UK). Glomerulosclerosis was evaluated as described
previously (Mu et al., 2005). The extent of glomerulosclerosis and
glomerular collapse was evaluated in each kidney by consecutive
examination under a light microscope. Tubulointerstitial injury was defined
as tubular dilation and/or atrophy or as interstitial fibrosis (Zeisberg and
Kalluri., 2004).
Tubular injuries were examined in at least 20 areas using the following
scoring system: 0, changes in <10% of the cortex; 1+, changes in up to 25%
of the cortex; 2+, changes in up to 50% of the cortex; and 3+, changes in
50% of the cortex sections.
Transmission electron microscopy analysis
1-mm3 of renal tissue was collected and fixed by incubation for 2 hours in
1.5% glutaraldehyde and 1% paraformaldehyde in cacodylate buffer (0.1 M,
pH 7.3). The tissue was post-fixed in 1% of osmium tetroxide in cacodylate
buffer (0.1 M, pH 7.3). After a series of ethanol dehydrations, the tissue was
resin-embedded. Ultrafine sections were sliced and colored with uranyl
acetate and lead citrate, and then exanimated and micro-photographed.
Statistical analysis
All data are presented as the mean±s.e.m. The differences among three or
more groups were compared using analysis of variance (ANOVA) with a
Tukey post-test. When two groups were compared, unpaired Student’s t-tests
were used. Significance was established as P<0.05. All statistical analyses
were performed using GraphPad PRISM (GraphPad, La Jolla, CA).
Competing interests
The authors declare they have no competing interests.
Author contributions
R.L.P., A.C.K., N.O.S.C. designed the experiments and/or the study. R.J.F.F.,
M.A.C., M.I.H., E.J.B., M.T.A., C.S.T.O., R.C.S., C.F.A., S.M.C., J.B.P., R.C.A.,
R.C.M., I.C.M., A.P.F. gave technical support. R.L.P. and N.O.S.C. wrote the paper.
Funding
This work was supported by Fundação de Amparo à Pesquisa do Estado de São
Paulo (FAPESP) [grant numbers 2012/05605-5 to R.L.P., 07/07139-3 and
12/02270-2] and Conselho Nacional de Desenvolvimento Científico e Tecnológico
(CNPq, INCT Complex Fluids and Renal Immunopathology Laboratory
INSERM/CNPq) [grant number 140739/2008-4 to R.L.P.]. The funders had no role
in study design, data collection and analysis, decision to publish or preparation of
the manuscript.
Supplementary material
Supplementary material available online at
http://dmm.biologists.org/lookup/suppl/doi:10.1242/dmm.014548/-/DC1
References
AbdAlla, S., Lother, H. and Quitterer, U. (2000). AT1-receptor heterodimers show
enhanced G-protein activation and altered receptor sequestration. Nature 407, 94-
98. 
AbdAlla, S., Lother, H., el Massiery, A. and Quitterer, U. (2001). Increased AT(1)
receptor heterodimers in preeclampsia mediate enhanced angiotensin II
responsiveness. Nat. Med. 7, 1003-1009. 
Abraham, W. M., Burch, R. M., Farmer, S. G., Sielczak, M. W., Ahmed, A. and
Cortes, A. (1991). A bradykinin antagonist modifies allergen-induced mediator
release and late bronchial responses in sheep. Am. Rev. Respir. Dis. 143, 787-796. 
Ahluwalia, A. and Perretti, M. (1996). Involvement of bradykinin B1 receptors in the
polymorphonuclear leukocyte accumulation induced by IL-1 beta in vivo in the
mouse. J. Immunol. 156, 269-274.
Bachvarov, D. R., Landry, M., Pelletier, I., Chevrette, M., Betard, C., Houde, I.,
Bergeron, J., Lebel, M. and Marceau, F. (1998). Characterization of two
polymorphic sites in the human kinin B1 receptor gene: altered frequency of an allele
in patients with a history of end-stage renal failure. J. Am. Soc. Nephrol. 9, 598-
604.
Bandeira-Melo, C., Calheiros, A. S., Silva, P. M., Cordeiro, R. S., Teixeira, M. M.
and Martins, M. A. (1999). Suppressive effect of distinct bradykinin B2 receptor
antagonist on allergen-evoked exudation and leukocyte infiltration in sensitized rats.
Br. J. Pharmacol. 127, 315-320. 
Barki-Harrington, L., Bookout, A. L., Wang, G., Lamb, M. E., Leeb-Lundberg, L. M.
and Daaka, Y. (2003). Requirement for direct cross-talk between B1 and B2 kinin
receptors for the proliferation of androgen-insensitive prostate cancer PC3 cells.
Biochem. J. 371, 581-587. 
Bhoola, K. D., Figueroa, C. D. and Worthy, K. (1992). Bioregulation of kinins:
kallikreins, kininogens, and kininases. Pharmacol. Rev. 44, 1-80.
Braun, C., Kleemann, T., Hilgenfeldt, U., Riester, U., Rohmeiss, P. and van der
Woude, F. J. (2002). Activity and functional significance of the renal kallikrein-kinin-
system in polycystic kidney disease of the rat. Kidney Int. 61, 2149-2156. 
Calixto, J. B., Cabrini, D. A., Ferreira, J. and Campos, M. M. (2000). Kinins in pain
and inflammation. Pain 87, 1-5. 
Campbell, D. J. (2001). The kallikrein-kinin system in humans. Clin. Exp. Pharmacol.
Physiol. 28, 1060-1065. 
Campos, M. M. and Calixto, J. B. (1995). Involvement of B1 and B2 receptors in
bradykinin-induced rat paw oedema. Br. J. Pharmacol. 114, 1005-1013. 
Chang, H. R., Yang, S. F., Lian, J. D., Lin, C. C., Wen, M. C., Chen, Y. T., Jan, Y. J.
and Hsieh, Y. S. (2009). Prediction of chronic allograft damage index of renal
allografts using serum level of plasminogen activator inhibitor-1. Clin. Transplant. 23,
206-212. 
Christopher, J. and Jaffa, A. A. (2002). Diabetes modulates the expression of
glomerular kinin receptors. Int. Immunopharmacol. 2, 1771-1779. 
Deegens, J. K., Steenbergen, E. J. and Wetzels, J. F. (2008). Review on diagnosis
and treatment of focal segmental glomerulosclerosis. Neth. J. Med. 66, 3-12.
Diamond, J. R. and Pesek-Diamond, I. (1991). Sublethal X-irradiation during acute
puromycin nephrosis prevents late renal injury: role of macrophages. Am. J. Physiol.
260, F779-F786.
Dos Santos, A. C., Roffê, E., Arantes, R. M., Juliano, L., Pesquero, J. L.,
Pesquero, J. B., Bader, M., Teixeira, M. M. and Carvalho-Tavares, J. (2008).
Kinin B2 receptor regulates chemokines CCL2 and CCL5 expression and modulates
leukocyte recruitment and pathology in experimental autoimmune encephalomyelitis
(EAE) in mice. J. Neuroinflammation 5, 49. 
Douillet, C. D., Velarde, V., Christopher, J. T., Mayfield, R. K., Trojanowska, M. E.
and Jaffa, A. A. (2000). Mechanisms by which bradykinin promotes fibrosis in
vascular smooth muscle cells: role of TGF-beta and MAPK. Am. J. Physiol. 279,
H2829-H2837.
Fogo, A. B. (2003). Animal models of FSGS: lessons for pathogenesis and treatment.
Semin. Nephrol. 23, 161-171. 
Franceschini, N., Hogan, S. L. and Falk, R. J. (2003). Primum non nocere: Should
adults with idiopathic FSGS receive steroids? Semin. Nephrol. 23, 229-233. 
Jeansson, M., Björck, K., Tenstad, O. and Haraldsson, B. (2009). Adriamycin alters
glomerular endothelium to induce proteinuria. J. Am. Soc. Nephrol. 20, 114-122. 
Kakoki, M., Sullivan, K. A., Backus, C., Hayes, J. M., Oh, S. S., Hua, K., Gasim, A.
M., Tomita, H., Grant, R., Nossov, S. B. et al. (2010). Lack of both bradykinin B1
and B2 receptors enhances nephropathy, neuropathy, and bone mineral loss in Akita
diabetic mice. Proc. Natl. Acad. Sci. USA 107, 10190-10195. 
Kang, D. S., Ryberg, K., Mörgelin, M. and Leeb-Lundberg, L. M. (2004).
Spontaneous formation of a proteolytic B1 and B2 bradykinin receptor complex with
enhanced signaling capacity. J. Biol. Chem. 279, 22102-22107. 
709
RESEARCH ARTICLE Disease Models & Mechanisms (2014) doi:10.1242/dmm.014548
Table 1. SYBR green primer sequences























Kim, J. H., Kim, B. K., Moon, K. C., Hong, H. K. and Lee, H. S. (2003). Activation of
the TGF-beta/Smad signaling pathway in focal segmental glomerulosclerosis.
Kidney Int. 64, 1715-1721. 
Klein, J., Gonzalez, J., Duchene, J., Esposito, L., Pradere, J. P., Neau, E. et al.
(2009). Delayed blockade of the kinin B1 receptor reduces renal inflammation and
fibrosis in obstructive nephropathy. FASEB J. 23, 134-142. 
LeBrun, C. J., Diehl, L. F., Abbott, K. C., Welch, P. G. and Yuan, C. M. (2000). Life
expectancy benefits of cancer screening in the end-stage renal disease population.
Am. J. Kidney Dis. 35, 237-243. 
Lee, H. S. (2012). Paracrine role for TGF-β-induced CTGF and VEGF in mesangial
matrix expansion in progressive glomerular disease. Histol. Histopathol. 27, 1131-
1141.
Lee, H. S. and Song, C. Y. (2010). Effects of TGF-beta on podocyte growth and
disease progression in proliferative podocytopathies. Kidney Blood Press. Res. 33,
24-29. 
Maltais, I., Bachvarova, M., Maheux, P., Perron, P., Marceau, F. and Bachvarov, D.
(2002). Bradykinin B2 receptor gene polymorphism is associated with altered urinary
albumin/creatinine values in diabetic patients. Can. J. Physiol. Pharmacol. 80, 323-
327. 
Marceau, F. and Bachvarov, D. R. (1998). Kinin receptors. Clin. Rev. Allergy Immunol.
16, 385-401. 
Marin Castaño, M. E., Schanstra, J. P., Hirtz, C., Pesquero, J. B., Pecher, C.,
Girolami, J. P. and Bascands, J. L. (1998). B2 kinin receptor upregulation by cAMP
is associated with BK-induced PGE2 production in rat mesangial cells. Am. J.
Physiol. 274, F532-F540.
Mu, W., Ouyang, X., Agarwal, A., Zhang, L., Long, D. A., Cruz, P. E., Roncal, C. A.,
Glushakova, O. Y., Chiodo, V. A., Atkinson, M. A. et al. (2005). IL-10 suppresses
chemokines, inflammation, and fibrosis in a model of chronic renal disease. J. Am.
Soc. Nephrol. 16, 3651-3660. 
Naito, T., Ma, L. J., Yang, H., Zuo, Y., Tang, Y., Han, J. Y., Kon, V. and Fogo, A. B.
(2010). Angiotensin type 2 receptor actions contribute to angiotensin type 1 receptor
blocker effects on kidney fibrosis. Am. J. Physiol. 298, F683-F691. 
Ng, Y. Y., Chen, Y. M., Tsai, T. J., Lan, X. R., Yang, W. C. and Lan, H. Y. (2009).
Pentoxifylline inhibits transforming growth factor-beta signaling and renal fibrosis in
experimental crescentic glomerulonephritis in rats. Am. J. Nephrol. 29, 43-53. 
Ni, A., Yin, H., Agata, J., Yang, Z., Chao, L. and Chao, J. (2003). Overexpression of
kinin B1 receptors induces hypertensive response to des-Arg9-bradykinin and
susceptibility to inflammation. J. Biol. Chem. 278, 219-225. 
Niemir, Z. I., Stein, H., Dworacki, G., Mundel, P., Koehl, N., Koch, B., Autschbach,
F., Andrassy, K., Ritz, E., Waldherr, R. et al. (1997). Podocytes are the major
source of IL-1 alpha and IL-1 beta in human glomerulonephritides. Kidney Int. 52,
393-403. 
Ohtaka, A., Ootaka, T., Sato, H., Soma, J., Sato, T., Saito, T. and Ito, S. (2002).
Significance of early phenotypic change of glomerular podocytes detected by Pax2
in primary focal segmental glomerulosclerosis. Am. J. Kidney Dis. 39, 475-485. 
Pereira, R. L., Buscariollo, B. N., Corrêa-Costa, M., Semedo, P., Oliveira, C. D.,
Reis, V. O., Maquigussa, E., Araújo, R. C., Braga, T. T., Soares, M. F. et al.
(2011). Bradykinin receptor 1 activation exacerbates experimental focal and
segmental glomerulosclerosis. Kidney Int. 79, 1217-1227. 
Pereira, R. L., Reis, V. O., Semedo, P., Buscariollo, B. N., Donizetti-Oliveira, C.,
Cenedeze, M. A., Soares, M. F., Pacheco-Silva, A., Savage, P. B., Câmara, N. O.
et al. (2012). Invariant natural killer T cell agonist modulates experimental focal and
segmental glomerulosclerosis. PLoS ONE 7, e32454. 
Phagoo, S. B., Reddi, K., Anderson, K. D., Leeb-Lundberg, L. M. and Warburton,
D. (2001). Bradykinin B1 receptor up-regulation by interleukin-1beta and B1 agonist
occurs through independent and synergistic intracellular signaling mechanisms in
human lung fibroblasts. J. Pharmacol. Exp. Ther. 298, 77-85.
Regoli, D. and Barabé, J. (1980). Pharmacology of bradykinin and related kinins.
Pharmacol. Rev. 32, 1-46.
Reis, V. O., Silva, J. C., Souza, G. T., Semedo, P., Buscariollo, B., Pereira, R. L.,
Cenedeze, M. A., Pacheco-Silva, A., Longo-Maugéri, I. M., Câmara, N. O. et al.
(2012). The polysaccharide fraction of Propionibacterium acnes modulates the
development of experimental focal segmental glomerulosclerosis. Immunobiology
217, 831-841. 
Ricupero, D. A., Romero, J. R., Rishikof, D. C. and Goldstein, R. H. (2000). Des-
Arg(10)-kallidin engagement of the B1 receptor stimulates type I collagen synthesis
via stabilization of connective tissue growth factor mRNA. J. Biol. Chem. 275, 12475-
12480. 
Roman-Campos, D., Duarte, H. L., Gomes, E. R., Castro, C. H., Guatimosim, S.,
Natali, A. J., Almeida, A. P., Pesquero, J. B., Pesquero, J. L. and Cruz, J. S.
(2010). Investigation of the cardiomyocyte dysfunction in bradykinin type 2 receptor
knockout mice. Life Sci. 87, 715-723. 
Sainz, I. M., Uknis, A. B., Isordia-Salas, I., Dela Cadena, R. A., Pixley, R. A.,
Colman, R. W. (2004). Interactions between bradykinin (BK) and cell adhesion
molecule (CAM) expression in peptidoglycan-polysaccharide (PG-PS)-induced
arthritis. FASEB J. 18, 887-889.  
Saleem, M. A., Ni, L., Witherden, I., Tryggvason, K., Ruotsalainen, V., Mundel, P.
and Mathieson, P. W. (2002). Co-localization of nephrin, podocin, and the actin
cytoskeleton: evidence for a role in podocyte foot process formation. Am. J. Pathol.
161, 1459-1466. 
Schanstra, J. P., Neau, E., Drogoz, P., Arevalo Gomez, M. A., Lopez Novoa, J. M.,
Calise, D., Pecher, C., Bader, M., Girolami, J. P. and Bascands, J. L. (2002). In vivo
bradykinin B2 receptor activation reduces renal fibrosis. J. Clin. Invest. 110, 371-379. 
Schramek, H., Sarközi, R., Lauterberg, C., Kronbichler, A., Pirklbauer, M., Albrecht,
R., Noppert, S. J., Perco, P., Rudnicki, M., Strutz, F. M. et al. (2009). Neuropilin-1
and neuropilin-2 are differentially expressed in human proteinuric nephropathies and
cytokine-stimulated proximal tubular cells. Lab. Invest. 89, 1304-1316. 
Seguin, T., Buleon, M., Destrube, M., Ranera, M. T., Couture, R., Girolami, J. P.
and Tack, I. (2008). Hemodynamic and renal involvement of B1 and B2 kinin
receptors during the acute phase of endotoxin shock in mice. Int. Immunopharmacol.
8, 217-221. 
Seikaly, M., Ho, P. L., Emmett, L. and Tejani, A. (2001). The 12th Annual Report of
the North American Pediatric Renal Transplant Cooperative Study: renal
transplantation from 1987 through 1998. Pediatr. Transplant. 5, 215-231. 
Souza, D. G., Pinho, V., Pesquero, J. L., Lomez, E. S., Poole, S., Juliano, L.,
Correa, A., Jr, de A Castro, M. S. and Teixeira, M. M. (2003). Role of the
bradykinin B2 receptor for the local and systemic inflammatory response that follows
severe reperfusion injury. Br. J. Pharmacol. 139, 129-139. 
Souza, D. G., Lomez, E. S., Pinho, V., Pesquero, J. B., Bader, M., Pesquero, J. L.
and Teixeira, M. M. (2004). Role of bradykinin B2 and B1 receptors in the local,
remote, and systemic inflammatory responses that follow intestinal ischemia and
reperfusion injury. J. Immunol. 172, 2542-2548.
Stadnicki, A., Pastucha, E., Nowaczyk, G., Mazurek, U., Plewka, D., Machnik, G.,
Wilczok, T. and Colman, R. W. (2005). Immunolocalization and expression of kinin
B1R and B2R receptors in human inflammatory bowel disease. Am. J. Physiol. 289,
G361-G366. 
Tunçdemir, M. and Oztürk, M. (2011). The effects of angiotensin-II receptor blockers
on podocyte damage and glomerular apoptosis in a rat model of experimental
streptozotocin-induced diabetic nephropathy. Acta Histochem. 113, 826-832. 
Wagner, M. C., Rhodes, G., Wang, E., Pruthi, V., Arif, E., Saleem, M. A., Wean, S.
E., Garg, P., Verma, R., Holzman, L. B. et al. (2008). Ischemic injury to kidney
induces glomerular podocyte effacement and dissociation of slit diaphragm proteins
Neph1 and ZO-1. J. Biol. Chem. 283, 35579-35589. 
Wang, D., Yoshida, H., Song, Q., Chao, L. and Chao, J. (2000a). Enhanced renal
function in bradykinin B(2) receptor transgenic mice. Am. J. Physiol. 278, F484-F491.
Wang, Y., Wang, Y. P., Tay, Y. C. and Harris, D. C. (2000b). Progressive adriamycin
nephropathy in mice: sequence of histologic and immunohistochemical events.
Kidney Int. 58, 1797-1804. 
Wang, P. H., Campanholle, G., Cenedeze, M. A., Feitoza, C. Q., Gonçalves, G. M.,
Landgraf, R. G., Jancar, S., Pesquero, J. B., Pacheco-Silva, A. and Câmara, N.
O. (2008). Bradykinin [corrected] B1 receptor antagonism is beneficial in renal
ischemia-reperfusion injury. PLoS ONE 3, e3050. 
Wang, P. H., Cenedeze, M. A., Campanholle, G., Malheiros, D. M., Torres, H. A.,
Pesquero, J. B., Pacheco-Silva, A. and Câmara, N. O. (2009). Deletion of
bradykinin B1 receptor reduces renal fibrosis. Int. Immunopharmacol. 9, 653-657. 
Westermann, D., Lettau, O., Sobirey, M., Riad, A., Bader, M., Schultheiss, H. P. and
Tschöpe, C. (2008). Doxorubicin cardiomyopathy-induced inflammation and apoptosis
are attenuated by gene deletion of the kinin B1 receptor. Biol. Chem. 389, 713-718. 
Westermann, D., Walther, T., Savvatis, K., Escher, F., Sobirey, M., Riad, A., Bader,
M., Schultheiss, H. P. and Tschöpe, C. (2009). Gene deletion of the kinin receptor
B1 attenuates cardiac inflammation and fibrosis during the development of
experimental diabetic cardiomyopathy. Diabetes 58, 1373-1381. 
Xia, C. F., Smith, R. S., Jr, Shen, B., Yang, Z. R., Borlongan, C. V., Chao, L. and
Chao, J. (2006). Postischemic brain injury is exacerbated in mice lacking the kinin
B2 receptor. Hypertension 47, 752-761. 
Zeisberg, M. and Kalluri, R. (2004). Experimental strategies to reverse chronic renal
disease. Blood Purif. 22, 440-445. 
Zheng, Z., Pavlidis, P., Chua, S., D’Agati, V. D. and Gharavi, A. G. (2006). An
ancestral haplotype defines susceptibility to doxorubicin nephropathy in the
laboratory mouse. J. Am. Soc. Nephrol. 17, 1796-1800. 
Zheng, J., Gong, J., Zhang, A., Li, S., Zeng, Z., Han, Y. and Gan, W. (2012).
Attenuation of glomerular filtration barrier damage in adriamycin-induced
nephropathic rats with bufalin: an antiproteinuric agent. J. Steroid Biochem. Mol.
Biol. 129, 107-114. 
Zuccollo, A., Navarro, M. and Catanzaro, O. (1996a). Effects of B1 and B2 kinin
receptor antagonists in diabetic mice. Can. J. Physiol. Pharmacol. 74, 586-589. 
Zuccollo, A., Navarro, M., Prendes, G. M., Dominguez, A. and Catanzaro, O. L.
(1996b). Effects of HOE 140 on some renal functions in type I diabetic mice. Arch.
Physiol. Biochem. 104, 252-254. 
Zychma, M. J., Gumprecht, J., Trautsolt, W., Szydlowska, I. and Grzeszczak, W.
(2003). Polymorphic genes for kinin receptors, nephropathy and blood pressure in
type 2 diabetic patients. Am. J. Nephrol. 23, 112-116. 
RESEARCH ARTICLE Disease Models & Mechanisms (2014) doi:10.1242/dmm.014548
D
is
ea
se
 M
od
el
s 
&
 M
ec
ha
ni
sm
s
